Profile data is unavailable for this security.
About the company
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
- Revenue in HKD (TTM)120.56m
- Net income in HKD-291.46m
- Incorporated2009
- Employees172.00
- LocationHua MedicineHua Medicine, 275 Ai Di Sheng RoadSHANGHAI 201203ChinaCHN
- Phone+86 2 158869997
- Websitehttps://www.huamedicine.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antengene Corp Ltd | 62.05m | -585.97m | 776.12m | 178.00 | -- | 0.7059 | -- | 12.51 | -0.95 | -0.95 | 0.1005 | 1.63 | 0.035 | 0.6597 | 1.57 | 308,681.80 | -33.06 | -53.57 | -37.16 | -58.94 | 84.84 | -- | -944.43 | -1,987.01 | 5.66 | -- | 0.1663 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
JW (Cayman) Therapeutics Co Ltd | 191.37m | -694.78m | 843.28m | 323.00 | -- | 0.5138 | -- | 4.41 | -1.68 | -1.68 | 0.4639 | 3.95 | 0.0747 | 1.87 | 11.48 | 480,819.20 | -27.11 | -39.77 | -31.71 | -44.00 | 50.40 | -- | -363.06 | -1,316.81 | 2.76 | -- | 0.2043 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
Sunho Biologics Inc | 0.00 | -118.73m | 853.83m | 124.00 | -- | 1.41 | -- | -- | -0.574 | -0.574 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.77 | -300.76 | 0.0516 | -- | -- | -- | -155.25 | -- | -- | -- |
Brii Biosciences Ltd | 0.00 | -293.74m | 943.20m | 95.00 | -- | 0.2976 | -- | -- | -0.4025 | -0.4025 | 0.00 | 4.34 | 0.00 | -- | -- | 0.00 | -8.89 | -- | -9.01 | -- | -- | -- | -- | -- | -- | -- | 0.007 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
Genor Biopharma Holdings Ltd | 16.01m | -581.53m | 1.02bn | 28.00 | -- | 0.8617 | -- | 63.97 | -1.15 | -1.15 | 0.0315 | 2.29 | 0.0093 | 0.0178 | 0.2277 | 153,966.80 | -33.87 | -55.46 | -39.06 | -63.73 | 97.59 | 66.56 | -3,638.27 | -14,819.18 | 5.73 | -- | 0.003 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
Immunotech Biopharm Ltd | 0.00 | -342.18m | 1.34bn | 201.00 | -- | 14.91 | -- | -- | -0.665 | -0.665 | 0.00 | 0.1744 | 0.00 | -- | -- | 0.00 | -35.21 | -37.42 | -55.75 | -45.48 | -- | -- | -- | -- | 0.3638 | -2.46 | 0.6119 | -- | -- | -- | -5.25 | -- | -8.46 | -- |
Wuhan YZY Biopharma Co Ltd | 0.00 | -203.09m | 1.35bn | 114.00 | -- | 24.59 | -- | -- | -1.07 | -1.07 | 0.00 | 0.2831 | 0.00 | -- | -- | 0.00 | -83.99 | -- | -230.17 | -- | -- | -- | -- | -- | 1.21 | -- | 0.7078 | -- | -- | -- | -1.50 | -- | -- | -- |
Hua Medicine | 120.56m | -291.46m | 1.46bn | 172.00 | -- | -- | -- | 12.08 | -0.2973 | -0.2973 | 0.123 | -0.0374 | 0.0779 | 1.51 | 3.31 | 681,105.00 | -18.84 | -25.61 | -23.63 | -28.81 | 37.72 | -- | -241.76 | -1,654.70 | 4.64 | -- | 1.14 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
Jacobio Pharmaceuticals Group Co Ltd | 25.66m | -400.47m | 1.52bn | 298.00 | -- | 1.52 | -- | 59.08 | -0.5159 | -0.5159 | 0.0331 | 1.27 | 0.016 | -- | 2.41 | 85,237.88 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
TOT Biopharm International Co Ltd | 1.08bn | 9.92m | 1.53bn | 572.00 | 144.76 | 1.91 | 21.78 | 1.42 | 0.0137 | 0.0137 | 1.48 | 1.04 | 0.6899 | 2.44 | 6.40 | 1,954,469.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
Mabpharm Ltd | 167.79m | -228.99m | 1.59bn | 297.00 | -- | 12.46 | -- | 9.46 | -0.0555 | -0.0555 | 0.0407 | 0.0309 | 0.164 | 0.1937 | 3.26 | 483,537.80 | -22.38 | -21.42 | -31.11 | -27.49 | 86.91 | -- | -136.47 | -486.40 | 0.6836 | -22.44 | 0.679 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
Frontage Holdings Corp | 2.02bn | 47.36m | 1.63bn | 1.66k | 34.92 | 0.6231 | 4.83 | 0.8067 | 0.0229 | 0.0229 | 0.9858 | 1.28 | 0.4701 | 56.23 | 4.58 | 1,147,743.00 | 1.06 | 4.46 | 1.30 | 5.28 | 28.56 | 34.00 | 2.26 | 9.92 | 1.25 | 2.37 | 0.311 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
Data as of Oct 09 2024. Currency figures normalised to Hua Medicine's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 31 Jul 2024 | 23.86m | 2.26% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 14.26m | 1.35% |
Allspring Global Investments LLCas of 30 Jun 2024 | 10.58m | 1.00% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.88m | 0.56% |
CRUX Asset Management Ltd.as of 31 Mar 2023 | 4.07m | 0.39% |
State Board of Administration of Florida Retirement Systemas of 30 Jun 2023 | 2.32m | 0.22% |
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 560.00k | 0.05% |
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 180.00k | 0.02% |
SSgA Funds Management, Inc.as of 03 Jul 2024 | 155.40k | 0.02% |
Norges Bank Investment Managementas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.